IART Stock Analysis: Integra LifeSciences | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.404m USD | 12M Return: 42.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.8M
EPS Trend: -94.3%
Qual. Beats: 1
Rev. Trend: 93.7%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Integra LifeSciences Holdings (NASDAQ: IART) is a U.S.-based medical device manufacturer organized into two reporting segments - Codman Specialty Surgical and Tissue Technologies - focused on surgical instruments, neurosurgery, neurocritical care, otolaryngology, and wound care products. Its neurosurgery portfolio spans tissue ablation, dural repair, CSF management, intracranial monitoring, and cranial stabilization, while its wound and tissue repair lines address acute wounds such as burns, chronic wounds including diabetic foot ulcers, and surgical applications such as hernia reinforcement, tendon protection, and peripheral nerve repair. The company also sells surgical headlamps, lighting, and instrumentation to hospitals, surgery centers, dental, podiatry, and veterinary offices, and operates an ear, nose, and throat business that includes balloon-based sinus and eustachian tube dilation technologies and surgical navigation systems.
The company distributes products through a mix of direct sales forces and third-party channels to hospitals, integrated health networks, group purchasing organizations (GPOs), clinicians, surgery centers, and other providers across the United States, Europe, Asia Pacific, and other international markets. As a Health Care Equipment company, Integras business model depends heavily on surgeon and hospital adoption, recurring procedure volume, and contracts with GPOs and integrated delivery networks - typical of the diversified medical devices sub-industry. The company was incorporated in 1989, is headquartered in Princeton, New Jersey, and adopted its current name in June 1995.
- Codman neurosurgery segment revenue accelerates on procedural volume recovery
- Tissue Technologies faces margin pressure from wound care competition
- European MDR regulation delays CE-marked product launches
| Net Income: -495.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 2.34 > 1.0 |
| NWC/Revenue: 50.18% < 20% (prev 3.24%; Δ 46.93% < -1%) |
| CFO/TA 0.02 > 3% & CFO 71.4m > Net Income -495.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.0m) vs 12m ago 0.64% < -2% |
| Gross Margin: 53.21% > 18% (prev 53.54%; Δ -0.33% > 0.5%) |
| Asset Turnover: 72.30% > 50% (prev 167.3%; Δ -94.95% > 0%) |
| Interest Coverage Ratio: -4.68 > 6 (EBIT TTM -441.6m / Interest Expense TTM 94.3m) |
| A: 0.23 (Total Current Assets 1.17b - Total Current Liabilities 346.8m) / Total Assets 3.58b |
| B: 0.12 (Retained Earnings 418.8m / Total Assets 3.58b) |
| C: -0.19 (EBIT TTM -441.6m / Avg Total Assets 2.27b) |
| D: 0.41 (Book Value of Equity 1.04b / Total Liabilities 2.54b) |
| Altman-Z'' = 1.02 = BB |
| DSRI: 1.03 (Receivables 264.4m/252.4m, Revenue 1.64b/1.62b) |
| GMI: 1.01 (GM 53.54% / 53.21%) |
| AQI: -0.88 (AQ_t 0.51 / AQ_t-1 -0.58) |
| SGI: 1.01 (Revenue 1.64b / 1.62b) |
| TATA: -0.16 (NI -495.8m - CFO 71.4m) / TA 3.58b) |
| Beneish M = -4.12 (Cap -4..+1) = AAA |
As of July 11, 2026, the stock is trading at USD 18.79 with a total of 941,880 shares traded. Over the past week, the price has changed by +4.10%, over one month by +9.95%, over three months by +89.80% and over the past year by +42.67%.
Current recommended Stop Loss: 17.70 (which is 5.8% or 1.3 ATR below the current price).
Integra LifeSciences has received a consensus analysts rating of 2.92. Therefore, it is recommended to hold IART.
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 2
- StrongSell: 2
| Analysts Target Price | 17.4 | -7.2% |
P/E Forward = 7.2727
P/S = 0.8539
P/B = 1.3352
P/EG = 0.7128
Revenue TTM = 1.64b USD
EBIT TTM = -441.6m USD
EBITDA TTM = -289.3m USD
Long Term Debt = 1.83b USD (from longTermDebt, last quarter)
Short Term Debt = 52.7m USD (from shortTermDebt, last quarter)
Debt = 2.21b USD (from shortLongTermDebtTotal, last quarter) + Leases 174.0m
Net Debt = 1.95b USD (calculated: Debt 2.21b - CCE 265.5m)
Enterprise Value = 3.35b USD (1.40b + Debt 2.21b - CCE 265.5m)
Interest Coverage Ratio = -4.68 (Ebit TTM -441.6m / Interest Expense TTM 94.3m)
EV/FCF = -331.2x (Enterprise Value 3.35b / FCF TTM -10.1m)
FCF Yield = -0.30% (FCF TTM -10.1m / Enterprise Value 3.35b)
FCF Margin = -0.62% (FCF TTM -10.1m / Revenue TTM 1.64b)
Net Margin = -30.15% (Net Income TTM -495.8m / Revenue TTM 1.64b)
Gross Margin = 53.21% ((Revenue TTM 1.64b - Cost of Revenue TTM 769.5m) / Revenue TTM)
Gross Margin QoQ = 57.22% (prev 49.52%)
Tobins Q-Ratio = 0.94 (Enterprise Value 3.35b / Total Assets 3.58b)
Interest Expense / Debt = 4.26% (Interest Expense 94.3m / Debt 2.21b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -348.9m (EBIT -441.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.38 (Total Current Assets 1.17b / Total Current Liabilities 346.8m)
Debt / Equity = 2.12 (Debt 2.21b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = -6.73 (negative EBITDA) (Net Debt 1.95b / EBITDA -289.3m)
Debt / FCF = -192.5 (out of range, set to none) (Net Debt 1.95b / FCF TTM -10.1m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.80% (Net Income -495.8m / Total Assets 3.58b)
RoE = -47.65% (Net Income TTM -495.8m / Total Stockholder Equity 1.04b)
RoCE = -15.40% (EBIT -441.6m / Capital Employed (Equity 1.04b + L.T.Debt 1.83b))
RoIC = -10.90% (negative operating profit) (NOPAT -348.9m / Invested Capital 3.20b)
WACC = 6.66% (E(1.40b)/V(3.62b) * Re(11.86%) + D(2.21b)/V(3.62b) * Rd(4.26%) * (1-Tc(0.21)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -34.10 | Cagr: -0.78%
[DCF] Fair Price = unknown (Cash Flow -10.1m)
EPS Correlation: -94.33 | EPS CAGR: -13.36% | SUE: 2.82 | # QB: 1
Revenue Correlation: 93.69 | Revenue CAGR: 2.96% | SUE: 1.10 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.48 | Chg30d=-8.64% | Revisions=-44% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.56 | Chg30d=-4.17% | Revisions=-30% | Analysts=9
EPS current Year (2026-12-31): EPS=2.45 | Chg30d=+0.05% | Revisions=+70% | GrowthEPS=+9.8% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=2.62 | Chg30d=+0.31% | Revisions=+44% | GrowthEPS=+6.9% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: +14% (up=15, down=11)